Navigation Links
Medtronic Updates Long-Term ENDEAVOR I-II Clinical Data Showing,Sustained Safety and Significant Reductions in Repeat Procedures

BARCELONA, Spain--(BUSINESS WIRE)--May 22, 2007 - Medtronic (NYSE:MDT) today presented new long-term data from the ENDEAVOR clinical trial program reinforcing the existing safety and efficacy profile of the Endeavor(R) drug-eluting coronary stent system. Four-year results from the 100-patient first-in-man ENDEAVOR I trial and three-year results from the nearly 1,200 patient ENDEAVOR II trial demonstrate that Endeavor is associated with sustained safety, significant reductions in repeat procedures and no late stent thrombosis in either trial using the pre-specified trial protocol definitions. The ENDEAVOR II study also showed that the Medtronic Driver(R) bare metal stent offers consistent and durable long-term clinical results.

The data was presented by Andreas Zeiher, M.D., J.W. Goethe-University, Frankfurt, Germany, during the EuroPCR's late-breaking clinical trial session. The Endeavor stent is approved in more than 100 countries worldwide and currently is under review by the U.S. Food and Drug Administration. FDA approval is anticipated in the second half of 2007.

The ENDEAVOR I data continue to show excellent long-term results, with only one clinical event between years three and four, a non-cardiac death from cancer. Target Lesion Revascularization (TLR) at four years was 3.1% and Target Vessel Revascularization (TVR) was 5.2%. The Major Adverse Cardiac Event (MACE) rate, one of the trial's primary endpoints, was 7.2%, with no late stent thrombosis events in this patient cohort.

Through three years of follow-up in the ENDEAVOR II trial, the TLR rate was 7.3%, compared to 14.7% for the Driver bare metal control arm (p= less than 0.001), representing a 50% reduction in the need for repeat procedures. Target Vessel Failure, the trial's primary endpoint, was 12.8% for Endeavor and 21.4% for Driver, a 40% reduction (p= less than 0.001). Endeavor showed a MACE rate of 12.0% at three years, compared
'"/>




Page: 1 2 3

Related medicine technology :

1. Medtronic Announces Positive Nine-Month Results for Endeavor Resolute Next Generation Drug-Eluting Stent at EuroPCR
2. Study Supports Cost-Effectiveness of Medtronics Spasticity Treatment for Children with Cerebral Palsy
3. Two-Year Results from the Medtronic ENDEAVOR III Trial Confirm Stents Positive Clinical Profile
4. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
5. Avalon Updates the AVN944 Phase I Hematologic Malignancies Trial
6. NCCN Updates Esophageal and Gastric Cancer Guidelines
7. Isis Pharmaceuticals Updates Its Positive Phase 2 Data for ISIS 301012 in Familial Hypercholesterolemia Patients
8. Anesiva Announces Phase 2 Data Showing Substantial, Long-Term Pain Reductions with Adlea(TM) (formerly 4975) in Osteoarthritis of the Knee
9. Long-Term Pegylated Interferon Alfa-2b Therapy in Stage III Melanoma Demonstrated Significant and Sustained Impact on Relapse-Free Survival
10. Surfaxin (Lucinactant) Long-Term Survival Advantage vs. Comparators Published in Pediatrics
11. Long-Term Extension of Ulcerative Colitis Study Shows Remicade Responders Maintained Improvement Through Two Years of Follow-Up
Post Your Comments:
(Date:6/18/2013)... , June 18, 2013  Healthgrades, the leading ... and connect with physicians and hospitals, today issued ... in" When Making Healthcare Decisions to Get Your ... performing hospitals for maternity care, gynecologic surgery, as ... of women across 15 of the most common ...
(Date:6/18/2013)... 18, 2013  Pro football player and 2012 most ... family expert Jo Frost have potentially life-threatening ... the fully integrated specialty pharmaceutical business of Mylan Inc. ... this significant health problem. In recognition of the 25 ... Administration (FDA) approval of EpiPen ® (epinephrine) Auto-Injector, ...
(Date:6/17/2013)... WASHINGTON , June 17, 2013 ... ) presented additional data today at ENDO 2013, ... demonstrating that tasimelteon can entrain (synchronize) both melatonin ... potential to reset the master body clock and ... Non-24-Hour Disorder (Non-24).  The SET (Safety and Efficacy ...
Breaking Medicine Technology:Healthgrades Recognizes Top Hospitals in Treatment of Maternity Care, Gynecologic Surgery and Women's Health 2Healthgrades Recognizes Top Hospitals in Treatment of Maternity Care, Gynecologic Surgery and Women's Health 3Healthgrades Recognizes Top Hospitals in Treatment of Maternity Care, Gynecologic Surgery and Women's Health 4Mylan Specialty L.P. Joins Forces with Adrian Peterson and Jo Frost to Launch Anaphylaxis Preparedness Campaign 2Mylan Specialty L.P. Joins Forces with Adrian Peterson and Jo Frost to Launch Anaphylaxis Preparedness Campaign 3Mylan Specialty L.P. Joins Forces with Adrian Peterson and Jo Frost to Launch Anaphylaxis Preparedness Campaign 4Mylan Specialty L.P. Joins Forces with Adrian Peterson and Jo Frost to Launch Anaphylaxis Preparedness Campaign 5Mylan Specialty L.P. Joins Forces with Adrian Peterson and Jo Frost to Launch Anaphylaxis Preparedness Campaign 6Mylan Specialty L.P. Joins Forces with Adrian Peterson and Jo Frost to Launch Anaphylaxis Preparedness Campaign 7Mylan Specialty L.P. Joins Forces with Adrian Peterson and Jo Frost to Launch Anaphylaxis Preparedness Campaign 8Vanda Presents Data From Phase III Studies that Demonstrate Tasimelteon Restores Daily Cortisol Rhythm In Blind Patients With Non-24-Hour Disorder 2Vanda Presents Data From Phase III Studies that Demonstrate Tasimelteon Restores Daily Cortisol Rhythm In Blind Patients With Non-24-Hour Disorder 3Vanda Presents Data From Phase III Studies that Demonstrate Tasimelteon Restores Daily Cortisol Rhythm In Blind Patients With Non-24-Hour Disorder 4
(Date:6/18/2013)... Healthcare Solutions , the parent ... today announced the appointment of Richard Leonardo to ... position, Leonardo will direct Healthcare Solutions’ national sales ... initiatives. , Recognized in the property and casualty ... more than 20 years of experience in business ...
(Date:6/18/2013)... New York, New York (PRWEB) June 18, 2013 ... forward in both state and federal court, a new report ... of more than 70,000 U.S. Food & Drug Administration (FDA) ... According to NewsChannel5 in Cleveland, Ohio, over 4.700 Mirena ... since 2008, while more than 1,300 have reportedly experienced uterine ...
(Date:6/18/2013)... By studying one of the most successful ... of successful strategies in his article What We Can ... Study. , The inspirational brand Gollan refers to is ... an impressive 62 million followers (and rising). , The ... Facebook Pages earlier this year. The Facebook data tracking publication ...
(Date:6/18/2013)... likely to keep their scheduled medical appointments and ... physician listens, explains things clearly and knows them as ... research suggests. , "If people feel their doctor really ... doctor has their best interests at heart and may ... leader Tabor E. Flickinger, M.D., M.P.H., a fellow in ...
(Date:6/18/2013)... research scientist Daniel Perlman has discovered a way to ... foods that are consumed by humans, potentially opening the ... A U.S. patent (#8,460,738) on the new process and ... Phytosterols in plants and cholesterol molecules in animals are ... are attracted to one another. When they mix in ...
Breaking Medicine News(10 mins):Health News:Healthcare Solutions Appoints Richard Leonardo to Chief Sales Officer 2Health News:Mirena Lawsuit News: Bernstein Liebhard LLP Comments on Mounting Reports of Mirena Side Effects, Including Device Migration, Uterine Perforations 2Health News:Mirena Lawsuit News: Bernstein Liebhard LLP Comments on Mounting Reports of Mirena Side Effects, Including Device Migration, Uterine Perforations 3Health News:Casey Gollan Shows What We Can Learn From One of the Best Facebook Pages There Is 2Health News:Casey Gollan Shows What We Can Learn From One of the Best Facebook Pages There Is 3Health News:Respect may be the key to stopping patient 'no shows' 2Health News:Brandeis scientist invents anti-cholesterol process 2
... to identifying high-risk behaviors among adolescents. Injury risk, ... leading causes of adolescent morbidity and mortality; yet pediatricians ... concerns. That paradox of care is the motivation behind ... Pediatrics, which found adolescents who participated in computerized screening ...
... adults and is emerging in the world of pediatrics. A ... D insufficiency, causes rickets in children and can be treated ... as increased sun exposure. , A new study ... the first study to investigate vitamin D insufficiency in pediatric ...
... 1 Aflac Incorporated,announced today that Martin A. Durant ... chief financial officer. Susan R. Blanck has been,promoted to ... are,effective June 1, 2008., Durant first joined Aflac ... He was with Aflac for 10 years, eventually serving ...
... Prenatal biochemical screening tests are widely used to look ... serious handicap, or even death during gestation or in the ... able to detect fewer than half of the total chromosomal ... conference of the European Society of Human Genetics tomorrow (Monday ...
... of particular gene respond well to targeted therapy , , ... who have the normal version of a particular gene ... that includes adding the targeted therapy Erbitux to chemotherapy. ... normal, or "wild-type" form of the gene, according to ...
... melanoma tumors may make the cancer more vulnerable to chemotherapy, ... Duke Comprehensive Cancer Center. , We tested a compound that ... on the surface of a melanoma cell," said Douglas Tyler, ... Medical Center, and senior investigator on this study. "When chemotherapy ...
Cached Medicine News:Health News:Waiting room gadget may prove to be a life-saver 2Health News:First study to examine vitamin D insufficiency in pediatric patients with low bone density 2Health News:Martin Durant Promoted to Executive Vice President and Deputy CFO; Sue Blanck Promoted to First Senior Vice President of Aflac Japan 2Health News:Martin Durant Promoted to Executive Vice President and Deputy CFO; Sue Blanck Promoted to First Senior Vice President of Aflac Japan 3Health News:Prenatal biochemical screening only detects half of chromosomal abnormalities 2Health News:Prenatal biochemical screening only detects half of chromosomal abnormalities 3Health News:Erbitux Works Well for Two-Thirds of Colon Cancer Patients 2Health News:Erbitux Works Well for Two-Thirds of Colon Cancer Patients 3Health News:Combination therapy packs 1-2 punch against melanoma 2
Delicate Desmarres lid retractors, round serrated handle, very thin blades, polished finish, size 1....
2.0 mm cup , straight shaft, Flat handle, length 125.0 mm....
Size 4 - 2.25 mm...
The Storz Protege is an anterior segment unit only....
Medicine Products: